There has already been preclinical suggestion that targeting the neuropeptide Y (NPY) pathway in the hypothalamus, which has a role in appetite regulation, could hold therapeutic promise via the NPY Y1 receptor in migraine, as the pathway shares a role in trigeminovascular nociception in an animal model [59]. This evidence concerns the gene NPY and migraine disorder.